BTG Shoots For $1 Billion With Focus On Interventional Medicine
This article was originally published in The Gray Sheet
The specialist-focused health care company is building a multi-asset interventional medicines business, including multiple drug-device combination products, which it expects will grow from $150 million in annual sales to more than $1 billion by fiscal 2021.
You may also be interested in...
The sale of BTG Specialty Pharmaceuticals to two affiliates of European specialty firm SERB leaves Boston Scientific with BTG’s interventional oncology and vascular products.
The $800m sale of BTG Specialty Pharmaceuticals business to SERB leaves Boston Scientific with BTG’s successful interventional oncology and vascular products.
BTG of Britain plans two new acquisitions, including a therapy for liver cancer that uses radioactive glass beads and a treatment for dissolving severe blood clots. The deals create an interventional medicine business with potential sales of $1 billion; BTG is funding much of the exercise through a share placement.